Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. It operates through the following segments: Biosimilars; Long-Acting Injectibles; and Administration and Unallocated. The Biosimilars segment include the operations of Xlucane as well as the pre-clinical biosimilars portfolio. The Long-Acting Injectibles comprises operations of Spherotide. The Administration and Unallocated segment consists remaining parts of the business and thereby for the most administration related posts. The company was founded by Jan-Willem de Gier, Marten Hellberg, and Samuel Wagner in 2008 and is headquartered in Solna, Sweden.